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| INTRODUCTION
Secondary prevention of venous thromboembolism (VTE), especially the optimum duration of treatment and which type and dosage of thromboprophylaxis is preferable, remains a topical and contentious point of debate for thrombosis experts around the globe.
1-4 Prominent collectives of thrombosis experts have tried to steer the debate in a more unified direction by issuing periodical best-practice treatment guidelines. The most widely used of these, published by the American
College of Chest Physicians (CHEST, formerly: ACCP), is referenced by physicians all over the world. Still, the lack of adherence to these guidelines is such that it has warranted a growing body of research devoted to this very problem. [5] [6] [7] [8] [9] Most of the studies on the subject retrospectively observe a single setting, which, while interesting, leaves important questions as to the generalizability of their findings. As each setting appears to face its own unique challenges, the overarching question of why there is so much variance between physicians when it comes to the secondary prevention of VTE is never fully addressed.
What could we do, then, to formulate a more universal answer to this question? In our view, a decent starting point would be to ask those who should know best: senior physicians involved in the treatment of VTE, whose stature in their local communities enables them to present a broader perspective. For this study, we interviewed 13 such physicians from a diverse range of countries, asking about the clinical practice of secondary prevention of VTE in their country. This paper details the accounts they gave, in which all aspects of VTE treatment were discussed, and area-specific barriers to treatment were identified.
| METHODS
From December 2015 to February 2016, we conducted 13 telephonebased, semi-structured interviews with an equal number of seniorlevel physicians in the field of thrombosis, all of who were at the time affiliated with medical centers participating in the Einstein Choice study. 10 We selected interviewee candidates on the basis of their considerable experience, stature, and organizational involvement in their respective local professional communities. The reasoning behind this selection strategy was that a prominent professional standing should confer a level of oversight and insight not afforded to physicians of lesser experience and lower professional status. Thirteen of the approached candidates were able and willing to participate in this study.
Among the selected participants were specialists involved in the management of anticoagulation clinics, specialists who had contributed to national treatment guidelines, and specialists who otherwise supervised or directed care in multiple medical centers in their country of employment. To protect the anonymity of our interviewees, no personally identifying details apart from gender pronouns appear in this paper or elsewhere.
The following themes were addressed in the interviews: which risk factors are considered in determining treatment and how these are weighted; type and duration of secondary prevention; barriers to treatment and reasons for discontinuing VTE treatment; the use of protocols, guidelines and risk scores, and country-specific circumstances regarding the provision of antithrombotic care ( Figure 1 ).
All of these themes were determined in advance of the interviews, based on the existing literature on the subject, including best-practice guidelines. 11, 12 The decision to include the theme on country-specific circumstances was informed by the regional and cultural diversity of countries from which our participants hailed.
Physicians from the following countries participated in this study:
the United States of America, Brazil, Canada, Hungary, Israel, the Netherlands, the Philippines, Poland, Russia, South Africa, Sweden,
Thailand, and Vietnam
All interviews were recorded and transcribed. In vivo coding 13 , ie, labeling transcript sections with phrases derived from the interviews, was used to organize research findings ( Figure 1) . Some of the interview excerpts that appear in this paper were minimally edited for clarity.
Medians and interquartile ranges (IQR) were computed for the physicians' self-reported years of experience, and self-estimated unique patients treated per annum.
| RESULTS
The average duration of a call was 28.2 minutes. The interviewed physicians had a median of 30 years (IQR: 18) of VTE treatment experience at the time of being interviewed, and treated a median of 125 (IQR: 175) unique patients per annum at the time of being interviewed.
| Universal risk factors
A diverse array of VTE recurrence risk factors emerged from the interviews (Table 1) . Although each interviewed physician stratified risk differently, 2 disease characteristics were universally identified as exerting the most influence on the secondary prophylaxis of VTE in the large majority of cases.
| Idiopathic or non-idiopathic
As a category, idiopathic cases of VTE, ie, cases of unknown etiology, were treated for longer periods of time than cases provoked by known and reversible risk factors (henceforth: provoked cases).
Most interviewees indicated that they tend to treat provoked cases for 3 months only; in particularly severe cases, exceptions to this rule were made and treatment carried on longer. If the event under examination constituted a recurrence, all interviewees favored indefinite anticoagulation therapy. Table 2 summarizes the responses of the interviewees when asked to provide a rough estimate of average treatment duration in their country for these three types of VTE.
| Proximal or distal
The distinction between proximal and distal VTE emerged as the second most important criterion in determining the duration of secondary prophylaxis. Like provoked VTEs, distal DVTs were largely treated for 3 months. Proximal VTEs were treated for at least 6 months.
| Area-specific aspects and barriers to VTE treatment
Venous thromboembolism treatment was not exclusively dictated by the relatively universal characteristics described thus far. Various area-specific features also influence and at times complicate treatment to varying degrees of intensity. The following is a summary of area-specific factors that affect VTE treatment in clinical practice, as reported by our interviewees.
| Cost of medication and health insurance
The interviewees indicated that the cost of drugs and health insurance policies significantly affect their decision-making in providing second- In South Africa, a particularly stark dichotomy was noted to exist between the public and private sectors. The South African interviewee recounted that in his country, it is exceedingly difficult for the financially destitute to get coverage for direct oral anticoagulants:
In the public sector [ In the Philippines, all drugs prescribed to outpatients have to be paid for out of pocket, which renders the DOACs unattainable at worst and unattractive at best for most patients. The Filipino interviewee lamented that even warfarin is out of reach for some: 
| Licensing status of pharmaceuticals
The local licensing status of pharmaceuticals represents a second practical barrier to treatment decision-making. After all, even if a DOAC might be a practitioner's first choice, its availability is not just contingent upon its supply chain, but also on its legal status.
The Russian interviewee related a situation where a drug's licensing status was mostly organized at the national level, but where local clinics and hospitals possessed the agency to make a case for the use of a drug for certain indications: 
My decision to prescribe novel oral anticoagulants is based on availability and on the possibility to get a li

| Pharmaceutical marketing
The Canadian interviewee suggested that aggressive pharmaceutical marketing often led to problems with therapy compliance in his country.
When asked about therapy non-compliance, he stated the following: 
The reason a patient's not compliant… I don't know if you have the same commercials [as we do] here […], but here, we get awful commercials of bleeding risks with Xarelto, health suits, and everything. And they want to stop treatment; yeah that happens. T A B L E 2 Reported average duration (in months) of secondary prophylaxis for different types of venous thromboembolism (VTE)
| Genetic profile of the populace
In some regions, populations were reported to be particularly predisposed to VTE on account of their genetic profile. As a consequence, thromboprophylaxis in these regions differed from that in other parts of the world. In Israel, for instance, thrombophilia was reported to afflict a much greater segment of the population than is common for many other parts of the world: 
| Climate
The Israeli interviewee noted that climate, although its role mostly goes unacknowledged by the literature, exerts a nontrivial impact on
VTE treatment in Israel:
We also give more concern than the literature to hydration 
| Alcohol abuse
Alcohol abuse was uniformly considered to pose multiple issues to effective secondary prophylaxis in VTE. In regions where alcohol abuse is particularly prevalent, it follows that treatment becomes a great deal more complicated. The Russian interviewee remarked the following on alcohol abuse in Russia, and how it affects VTE secondary prophylaxis decision-making in his country: 
| Drug-drug interactions
The Filipino interviewee reported that food supplement use is highly prevalent in the Philippines, and that these frequently interfere with 
| Pre-existing comorbidity
In 
| Lack of access to reliable health care
Adequate thromboprophylaxis requires adequate resources. In countries that are overall less affluent, medical resources and facilities are often few and far between. Three interviewees mentioned how a lack of access to reliable health care impedes adequate care for VTE patients in their respective countries.
The South African interviewee reported that treatment must sometimes be discontinued due to this barrier: 
| Guidelines, protocols and risk scores
Eleven out of 13 (84.6%) interviewees indicated that they incorporate treatment guidelines in their decision-making with some frequency.
The CHEST guidelines were mentioned a total of 8 times (61.5% of interviewees), equally as often as local guidelines. In addition, 50% of interviewees indicating use of local guidelines stated that they simultaneously reference the CHEST guidelines. The interviewees representing Poland, South Africa, Sweden, and Thailand explicitly noted that their local guidelines were either abbreviated versions of the CHEST guidelines, or at least largely based on these same guidelines.
Most interviewees considered the guidelines useful referential frameworks, but stated that they would deviate from the guidelines' recommendations in cases where they considered these insufficient or inappropriate based on current published evidence, or even personal experience. As area-specific circumstances were also not always accurately reflected in general treatment guidelines, some recommendations were considered inapplicable. Finally, some physicians said of the guidelines that they were simply too unwieldy for everyday use.
According to these physicians, the development of VTE-specific risk scores could benefit practitioners who are uninclined to turn to a hefty manual to inform their decisions.
Five (38.5%) of the interviewed physicians stated that they regularly employ risk scores to help inform decision-making. The HAS-BLED risk score 14 was deemed particularly useful; 4 out of 5 interviewees indicating risk score use stated that they frequently employed the HAS-BLED score. All four HAS-BLED users (Brazil, Canada, Poland, the Netherlands) indicated cognizance of the score's original purpose, yet hailed its usefulness and applicability to bleeding risk assessment in VTE, especially in the absence of a dedicated VTE bleeding risk score.
Other risk scores that were mentioned by the interviewees were the "Men continue and HER DOO2" clinical decision rule proposed in the REVERSE 15 cohort study (Canada), the Padua risk score for VTE (Philippines) 16 and the Caprini score for DVT (Philippines). This was especially apparent with regard to the discussion on optimum treatment duration. Recall the South African situation, where the typical comorbidity profile of a VTE patient is such that there is no point in even considering anything other than indefinite treatment. Or a country like Russia, where alcoholism is so prevalent that many patients prefer a higher risk of VTE recurrence over longerterm treatment.
As for the question of which drug to prescribe, two specific issues dominated the discussion. Firstly, physicians were limited in their treatment options by the cost of drugs and the health insurance plans available to their patients. In the most extreme case, that of the Philippines, patients often had no other choice but to take aspirin due to the high cost of VKAs and DOACs. In VKA-majority countries, too, physicians indicated that they were constrained in their options: even if some felt that VKAs fell short in a number of ways, and that prescribing a DOAC might be preferable in some cases, the relatively high cost of these drugs prevented them from doing so in any case. The reason for many of the interviewed physicians to prefer DOACs was twofold:
the desire to unburden patients, and more importantly, the need to improve therapy efficacy. In many countries, INR monitoring is patently inadequate, resulting in less efficacious treatment. Moreover, for many patients in these same countries traveling to a remote hospital or clinic is often difficult as well. The fixed-dose DOACs would clearly obviate these issues. An additional benefit of DOACs versus VKAs would be the relative lack of dietary and drug interactions, which would benefit countries like Russia and the Philippines. Notwithstanding the other ways in which VKAs and DOACs exhibit significant differences that one should expect to influence decision-making in this regard (eg, the absence of antidotes for all but one of the DOACs, which renders bleedings riskier), this convenience argument is one that carried considerable weight to the interviewees.
The second most brought up issue was that of therapy noncompliance. As the interview excerpts in this paper show, there were effectively two reasons for non-compliance under the status quo of secondary prophylaxis of VTE: either the patient perceived treatment as too much of an encumbrance, or they had insufficient access to the health care they required.
| Limitations
Given the small sample size, we acknowledge that the views expressed in these interviews may not be exhaustive or representative for all specialists in the surveyed countries. Additionally, the fact that interviewees were selected by a single individual (MHP) may have impacted on the selection of the final sample.
| CONCLUSION
With the expert interviews that formed the basis of this study, our aim was to elucidate the varying real-world experiences of VTE secondary prophylaxis decision-making in a contextually disparate set of countries around the world. Understanding when and where risk factors coincide, and when, where and why they vary could benefit medical practitioners and policymakers striving to implement better treatment standards.
In our view, the interviews presented in this paper raise the question whether universal guidelines are sufficient to aid the decision-making of physicians facing various local idiosyncrasies. Our tentative conclusion in this regard is that generalizing across highly dissimilar clinical realities will likely not result in universally applicable recommendations, and that a more decentralized approach may be preferable. Although the universal guidelines currently in use clearly serve their purpose in many ways, physicians may benefit from supplemental local guidelines that are more closely attuned to situations they are familiar with. In any case, these interviews hint at a multiplicity of reasons why adherence to the existing guidelines is still less than optimal.
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